This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
=== Clinical trials === Phase II clinical trials are in progress for treatment of endometrial cancer, diffuse large B-cell lymphoma, cholangiocarcinoma, and non-Hodgkin lymphoma. Copanlisib in combination with R-CHOP or R-B (rituximab and bendamustine) is in a phase III trial for relapsed indolent non-Hodgkin lymphoma (NHL). Two separate phase III trials are investigating the use of copanlisib in combination with rituximab for indolent NHL and the other using copanlisib alone in cases of rituximab-refractory indolent NHL. In a preclinical study, copanlisib was effective in inhibiting HER2+ breast cancer cells with acquired resistance to the HER2-inhibitors trastuzumab and/or lapatinib. This effect was increased when copanlisib was administered along with the aforementioned HER2-inhibitors. Consequently, treatments of copanlisib with trastuzumab are being clinically trialled in HER2-positive breast cancer patients.
The player's main method of defeating guests is with Combat pages, items used to attack and defend in combat through predetermined actions. The number of Combat Pages usable in a single Scene is equal to the number of Speed Dice a character has. Attacks deal both physical and stagger damage, affecting characters' HP and SR respectively. If a character's SR reaches zero, they will be unable to move and receive fatal damage from all attacks until their SR resets the next turn. A character dies (for the ongoing reception) if their HP reaches 0. Upon starting the Scene, all characters' Speed dice will randomly roll a low or high number or value, determining its Speed and the order of characters' actions. Librarians can redirect Combat pages towards them if they possess higher Speed than their target. Most characters (except bosses) start a reception with 1 or 2 Speed dice. If a librarian redirects a Combat page or opposes a Combat page directed at them, they enter a clash where both sides' Combat pages' actions interact with each other. Two dice will roll and the highest value will act; if both dice roll the same value, actions will be canceled out. Else, the attack counts as a one-sided action where attacks are not opposed. The player needs to carefully manage available resources, namely 'Light' (a form of combat stamina) and Combat pages, which return into the deck to be randomly picked upon usage. If the librarian's current Light is lower than the cost of any available Combat page, or if the librarian has no Combat pages to initiate action, they will be unable to act.
=== UK === In the UK, clinical psychologists undertake a Doctor of Clinical Psychology (DClinPsych), which is a practitioner doctorate with both clinical and research components. This is a three-year full-time salaried program sponsored by the National Health Service (NHS) and based in universities and the NHS. Entry into these programs is highly competitive and requires at least a three-year undergraduate degree in psychology plus some form of experience, usually in either the NHS as an assistant psychologist or in academia as a research assistant. It is not unusual for applicants to apply several times before being accepted onto a training course as only about one-fifth of applicants are accepted each year. These clinical psychology doctoral degrees are accredited by the British Psychological Society and the Health and Care Professions Council (HCPC). The HCPC is the statutory regulator for practitioner psychologists in the UK. Those who successfully complete clinical psychology doctoral degrees are eligible to apply for registration with the HPC as a clinical psychologist. In the UK, registration as a clinical psychologist with the Health and Care Professions Council (HCPC) is necessary. The HCPC is the statutory regulator for practitioner psychologists in the UK. In the UK the following titles are restricted by law "registered psychologist" and "practitioner psychologist"; in addition, the specialist title "clinical psychologist" is also restricted by law.
Dermorphin is a hepta-peptide first isolated from the skin of South American frogs belonging to the genus Phyllomedusa. The peptide is an agonist with high potency and selectivity to mu opioid receptors. Dermorphin is about 30–40 times more potent than morphine. The amino acid sequence of dermorphin is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. Dermorphin is not found in humans or other mammals and similar D-amino acid containing peptides have only been found in bacteria, amphibians, and molluscs. Dermorphin appears to be made via the posttranslational modification of a precursor peptide by an amino acid isomerase. This unusual process is needed because the D-alanine in this peptide is not part of the standard genetic code.
Sources: en.wikipedia.org
=== November === November 1 The U.S. Supreme Court begins its arguments about the Texas Heartbeat Act. Kenosha unrest shooting: The trial of Kyle Rittenhouse begins in Kenosha. November 2 New Jersey and Virginia gubernatorial elections are held. Republican Glenn Youngkin wins the Virginia race, while Democrat Phil Murphy wins re-election in the New Jersey race. Republican Winsome Sears wins the Virginia lieutenant governor's race and will become the first black and first female lieutenant governor of the state of Virginia. A special election is held in Ohio to fill a vacancy in its 11th congressional district left by Marcia Fudge when she resigned to become President Biden's Secretary of Housing and Urban Development. Democrat Shontel Brown wins with 81,636 of the 103,565 votes cast (78.8%). Another special election is held in Ohio to fill a vacancy in its 15th congressional district due to the resignation of Steve Stivers effective May 15 to become president and CEO of the Ohio Chamber of Commerce. Republican Mike Carey wins with 93,255 of the 160,012 votes cast (58.3%). The Atlanta Braves win the 2021 World Series, defeating the Houston Astros. Las Vegas Raiders wide receiver Henry Ruggs III is involved in an automobile accident where a 23-year-old woman is killed. At the time of the crash, Ruggs was driving 120 mph (190 km/h). He was also over double the legal intoxication level as well. The Raiders immediately cut him later that day.
===== Triangular nanoprisms ===== Triangular-shaped nanoparticles are a canonical type of anisotropic morphology studied for both gold and silver. Though many different techniques for silver nanoprism synthesis exist, several methods employ a seed-mediated approach, which involves first synthesizing small (3-5 nm diameter) silver nanoparticles that offer a template for shape-directed growth into triangular nanostructures. The silver seeds are synthesized by mixing silver nitrate and sodium citrate in aqueous solution and then rapidly adding sodium borohydride. Additional silver nitrate is added to the seed solution at low temperature, and the prisms are grown by slowly reducing the excess silver nitrate using ascorbic acid. With the seed-mediated approach to silver nanoprism synthesis, selectivity of one shape over another can in part be controlled by the capping ligand. Using essentially the same procedure above but changing citrate to poly (vinyl pyrrolidone) (PVP) yields cube and rod-shaped nanostructures instead of triangular nanoprisms. In addition to the seed mediated technique, silver nanoprisms can also be synthesized using a photo-mediated approach, in which preexisting spherical silver nanoparticles are transformed into triangular nanoprisms simply by exposing the reaction mixture to high intensities of light.
A man is arrested on suspicion of attempted murder after four people were injured when they were hit by a car being driven on the wrong side of the road in Shaftesbury Avenue, central London. King Charles III delivers the Royal Christmas Message from London's Fitzrovia Chapel, where he praises health workers and calls for unity following the summer riots. Archbishop of York Stephen Cottrell delivers a Christmas message in place of the Archbishop of Canterbury, doing so as he prepares to assume acting charge of the Church of England. 26 December – Data collected by MRI Software indicates a 4% decrease in the number of Boxing Day shoppers compared to the same day in 2023. 27 December The Prime Minister pays tribute to Nick Starmer, his younger brother who died from cancer the previous day. Conservative leader Kemi Badenoch expresses her condolences. Flights to and from some of the UK's major airports, including Gatwick and Manchester, are disrupted due to fog. Former Conservative Justice Secretary David Gauke, who is leading a review into sentencing and prison overcrowding, calls for greater use of open prisons in order to ease the pressure on closed category prisons. A man is charged with four counts of attempted murder and remanded in custody over an incident involving a car in London on Christmas Day. 28 December – Fog continues to disrupt flights at UK airports. 29 December Weather warnings for rain, snow, and winds of up to 70 mph are issued for parts of the UK on New Year's Eve and New Year's Day.
Sources: en.wikipedia.org
Subcutaneous administration of parathyroid hormone into the abdomen produces a rapid increase in plasma parathyroid hormone levels which reach peak at 1 to 2 hours after dosing. The mean half-life is approximately 1.5 hours. The absolute bioavailability of 100 micrograms of Preotact after subcutaneous administration in the abdomen is 55%.
=== Content protection === DisplayPort 1.0 includes optional DPCP (DisplayPort Content Protection) from Philips, which uses 128-bit AES encryption. It also features full authentication and session key establishment. Each encryption session is independent, and it has an independent revocation system. This portion of the standard is licensed separately. It also adds the ability to verify the proximity of the receiver and transmitter, a technique intended to ensure users are not bypassing the content protection system to send data out to distant, unauthorized users. DisplayPort 1.1 added optional implementation of industry-standard 56-bit HDCP (High-bandwidth Digital Content Protection) revision 1.3, which requires separate licensing from the Digital Content Protection LLC. DisplayPort 1.3 added support for HDCP 2.2, which is also used by HDMI 2.0.
Glucocorticoid injections are often used for acute and localized flare-ups. About 0.1% to 0.8% of the population is affected, with onset typically occurring in young adults. While men and women are equally affected with AS, women are more likely to experience inflammation rather than fusion.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.